Royalty Report: Delivery, Medical, Device – Collection: 164315

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Delivery
  • Medical
  • Device
  • Drugs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 164315

License Grant
The Irish Licensor grants the Licensee of Bermuda an exclusive license to the Licensors Technology for all research, development, and commercial purposes solely in the Field, but not beyond the Field.

Licensor grants the Licensee a non-exclusive license, or, if applicable, sublicense, to use the Licensors Trademarks, upon or in relation to the promotion, marketing, advertising, sale or offering for sale of the Licensors Royalty Products.

License Property
The trademark license includes Medipad(TM) and Elan(R).

The Licensors Medipad System Patent Portfolio includes, among others, patents and applications for Method and Device for Entrapping a Volume of Gas in a Liquid Drug Container,  Improved Method of Packaging a Drug Delivery Kit,  Cartridge-Based Drug Delivery Device and Medicament Delivery Device.

Medipad/TM/ is a lightweight, disposable drug delivery system, which combines the simplicity of a patch with the extensive delivery capabilities of an infusion pump.

Field of Use
The field of use is for the research, development, and commercialization of Iron chelating agents and the Substitute Compounds.

IPSCIO Record ID: 233493

License Grant
The Licensee of Bermuda wishes the Licensor of Bermuda to develop the System as a method of drug delivery incorporating the compound for the Field.

The Licensor of Bermuda grants to the Licensee of Bermuda an exclusive license to the Licensors Background Technology and Licensors Improvements to package, import, use, offer for sale and sell and otherwise distribute the Product for the Field in the Territory.

Licensor also grants a non-exclusive license in the Territory to use the Licensors Trademark solely for the purposes of exercising its rights and performing its obligations under this Agreement.

License Property
The patents and technology are for Medipad, and, an Improved Method of Packaging a Drug Delivery Kit .

The Compound shall mean any formulations of Desferoxamine and any of its analogues, isomers or derivatives.

The System shall mean the ambulatory subcutaneous infusion drug delivery system for direct attachment to the body of a patient having a flexible diaphragm drug reservoir, which is capable of delivering factory pre-programmed continuous amounts of drug upon activation as disclosed and described in the Licensors patents.

Deferoxamine (DFOA) is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.

Field of Use
The field shall mean the treatment of any iron overloading disorder by subcutaneously delivering the Compound using the System.

IPSCIO Record ID: 240465

License Grant
The Irish Licensor hereby grants to Licensee for the Term, and Licensor hereby accepts,

(i)  an exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property in connection with the applications or deliveries of compounds listed, except with respect to any Retained Licensor Intellectual Property, as to which Licensee is being granted a non-exclusive license
(ii) a non-exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property in connection with the applications or deliveries of compounds listed on Appendix E, and
(iii) subject to existing contractual rights of third parties, an exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property for use with any other compounds not listed on Appendices D or E and which are not Licensor Compounds.  

In each case for use only as Auto-Injector Technology and in the Field for the Territory to develop, make, have made, manufacture, have manufactured, package, use, import, export, promote, distribute, market, offer for sale, and sell the Devices and Products in the Field for the Territory.

License Property
Device shall mean any device or any parts or components thereof, the manufacture, use, importation or sale of which is covered by or embodies the Auto-Injector Technology, the Licensor Intellectual Property, the Joint Intellectual Property and the Licensee Intellectual Property.

Auto-Injector Technology shall mean any technology incorporated or used in a device (i) constituting a disposable, single use, needle injection system wherein the active ingredient is housed in a vial which is situated in a manner substantially perpendicular to the body surface, (ii) utilizing gas generation achieved via a chemical reaction for delivery of the active ingredient and (iii) having infusion time for delivery of an active ingredient which is less than or equal to 10 seconds. For the  avoidance of doubt, Auto-Injector Technology shall not include any other technology that does not meet the foregoing definition, whether or not similar or containing elements of the Licensor Intellectual Property, including, without limitation, the Medipad(TM) Technology or any other Excluded Technology.

Licensor Know-How shall mean all knowledge, information, trade secrets, data and expertise relating to the Licensor Patents for use in the Field and that is owned or licensed by Licensor (other than the Excluded Technology) as of the Effective Date, including, but not limited to, clinical data and test results, whether or not covered by any patent, copyright, design, trademark, trade secret or other industrial or intellectual property rights, but, except as otherwise provided herein, all subject to any contractual obligations to unaffiliated third parties that Licensor has as of the Effective Date.

Joint Intellectual Property shall mean the Joint Know-How and/or the Joint Patent Rights.

Joint Patent Rights shall mean any patent and patent applications created, developed, conceived or otherwise jointly invented or developed by Licensor and Licensee, relating to the Auto-Injector Technology.  Joint Patent Rights shall also include all extensions, continuations, continuations-in-part, divisionals, patents of additions, re-examinations, re-issues, supplementary protection certificates and foreign counterparts of such patents and patent applications and any patents issuing thereon and extensions of any patents licensed hereunder.

Licensor Compounds shall mean, at any time during the Term of this Agreement or, in the event of the acquisition of Licensor by another pharmaceutical company, immediately prior to the time of such acquisition, chemical entities (i) for which Licensor is the patent holder or which are in-licensed by Licensor or (ii) which are not patented and which Licensor is developing to sell itself In Market.

Field of Use
Field shall mean the practice of delivering therapeutic entities utilizing Auto Injector Technology, other than (A) active ingredients used in the treatment of  (i) central nervous system disorders, (ii) pain, (iii) male erectile dysfunction, and (iv) gene therapy and gene delivery and (B) Licensor Compounds, provided, in the case of Licensor Compounds that Licensee has not previously sub- licensed the right to use the Auto-Injector Technology with respect to such compound to an unaffiliated third party on an exclusive basis pursuant to a written agreement and that Licensee has delivered to Licensor prior written notice of same.

IPSCIO Record ID: 286035

License Grant
Licensee is entering into a licensing agreement to further develop, manufacture and have manufactured and to market, sell and distribute the products in the territory without infringing the Licensors Glucose Monitor Technology.

The Licensor of Ireland shall remain proprietor of the Licensors Glucose Monitor Technology but  grants to Licensee for the term a sole and exclusive license in the territory, with the right to grant sublicenses, to research, develop, manufacture, have manufactured for Licensee, import and have imported, use, sell, offer for sale and otherwise commercialize the Glucose Monitor Technology, Licensors interest in the joint improvements in the field and the products.

Licensor grants an exclusive license in the territory solely for use in connection with the sale of the product, for the term to use any Licensor trademark, if any, which relates to the Licensors Glucose Monitor Technology applicable to the product.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor has technology in relation to the development and production of monitoring devices and drug delivery devices and processes.

Licensor is knowledgeable in the development of devices and methods for directly or indirectly monitoring the concentration of glucose in a subject and has developed unique monitoring devices and methods.

The patents are for Analyte Controlled Liquid Delivery Device and Analyte Monitor; and, Improved Glucose Monitor.

Field of Use
Field shall mean the direct or indirect monitoring of the concentration of glucose in a subject.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.